JP7629453B2 - 小児用トラゾドン組成物およびその治療法 - Google Patents

小児用トラゾドン組成物およびその治療法 Download PDF

Info

Publication number
JP7629453B2
JP7629453B2 JP2022518971A JP2022518971A JP7629453B2 JP 7629453 B2 JP7629453 B2 JP 7629453B2 JP 2022518971 A JP2022518971 A JP 2022518971A JP 2022518971 A JP2022518971 A JP 2022518971A JP 7629453 B2 JP7629453 B2 JP 7629453B2
Authority
JP
Japan
Prior art keywords
trazodone
pediatric
pharmaceutical composition
treatment
children
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022518971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549473A (ja
JP2022549473A5 (enExample
Inventor
ファブリツィオ カリスティ
ロレッラ ラーニ
セレーナ トンジャーニ
ロッセッラ ピコッロ
ラウラ オッジャーヌ
Original Assignee
アンジェリーニ ソシエタ ペル アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンジェリーニ ソシエタ ペル アチオニ filed Critical アンジェリーニ ソシエタ ペル アチオニ
Publication of JP2022549473A publication Critical patent/JP2022549473A/ja
Publication of JP2022549473A5 publication Critical patent/JP2022549473A5/ja
Application granted granted Critical
Publication of JP7629453B2 publication Critical patent/JP7629453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022518971A 2019-09-26 2020-09-25 小児用トラゾドン組成物およびその治療法 Active JP7629453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906166P 2019-09-26 2019-09-26
US62/906,166 2019-09-26
PCT/EP2020/077017 WO2021058810A1 (en) 2019-09-26 2020-09-25 Pediatric trazodone compositions and method of treatment thereof

Publications (3)

Publication Number Publication Date
JP2022549473A JP2022549473A (ja) 2022-11-25
JP2022549473A5 JP2022549473A5 (enExample) 2023-08-01
JP7629453B2 true JP7629453B2 (ja) 2025-02-13

Family

ID=72665264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518971A Active JP7629453B2 (ja) 2019-09-26 2020-09-25 小児用トラゾドン組成物およびその治療法

Country Status (13)

Country Link
US (1) US12514856B2 (enExample)
EP (1) EP4034117A1 (enExample)
JP (1) JP7629453B2 (enExample)
KR (1) KR102936358B1 (enExample)
CN (1) CN114615983A (enExample)
AU (1) AU2020354534B2 (enExample)
BR (1) BR112022005343A2 (enExample)
CA (1) CA3153639A1 (enExample)
GE (2) GEP20257739B (enExample)
IL (1) IL291548A (enExample)
MX (1) MX2022003442A (enExample)
UA (1) UA129270C2 (enExample)
WO (1) WO2021058810A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173315A1 (en) * 2022-11-14 2024-05-30 OWP Pharmaceuticals, Inc. Trazodone oral solution
US20240390277A1 (en) * 2023-04-15 2024-11-28 Rubicon Research Private Limited Liquid formulations of trazodone
CN119280155B (zh) * 2024-12-11 2025-02-25 新基元(北京)医药科技有限公司 一种改善稳定性的盐酸曲唑酮液体药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534703A (ja) 2007-07-31 2010-11-11 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ トラゾドン系の安定な液状医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1931346T1 (sl) 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
ITMI20071603A1 (it) 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534703A (ja) 2007-07-31 2010-11-11 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ トラゾドン系の安定な液状医薬組成物

Also Published As

Publication number Publication date
JP2022549473A (ja) 2022-11-25
IL291548A (en) 2022-05-01
CA3153639A1 (en) 2021-04-01
GEAP202415936A (en) 2024-10-28
WO2021058810A1 (en) 2021-04-01
MX2022003442A (es) 2022-07-11
BR112022005343A2 (pt) 2022-06-14
GEP20257739B (en) 2025-02-25
US12514856B2 (en) 2026-01-06
KR102936358B1 (ko) 2026-03-10
EP4034117A1 (en) 2022-08-03
KR20220080096A (ko) 2022-06-14
US20220331312A1 (en) 2022-10-20
UA129270C2 (uk) 2025-03-05
AU2020354534B2 (en) 2025-10-02
CN114615983A (zh) 2022-06-10
AU2020354534A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
ES2929133T3 (es) Composiciones y métodos para la absorción transmucosa
US20230233537A1 (en) Compositions and Kits of Parts Comprising N,N-Dimethyltryptamine and Harmine and Their Use in Therapy
US12514856B2 (en) Pediatric trazodone compositions and method of treatment thereof
Cuzzolin Neonates exposed to excipients: concern about safety
JP2025003983A (ja) うつ病の治療のためのエスケタミン
KR20150058243A (ko) 아픽사반 액체 제제
Nielsen et al. Topical morphine for oral mucositis in children: dose finding and absorption
Marçon et al. Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin
CN110035741B (zh) 包含托莫西汀盐酸盐的口服溶液及其方法
Xiong et al. Effective doses of midazolam oral solution for the prevention of preoperative anxiety in paediatric patients
US20190388341A1 (en) Chewable gel dosage form and associated methods
Van Hecken et al. Relative bioavailability of enalapril administered as orodispersible minitablets in healthy adults
JP2023530500A (ja) てんかんの治療におけるカンナビジオールの使用
US20250319067A1 (en) Improved Pharmacokinetics of Tryptamine Prodrugs
JP6410814B2 (ja) フェキソフェナジンを含む経口投与用液体医薬組成物
Li et al. Pediatric cardiovascular drug trials, lessons learned
EA047917B1 (ru) Композиции тразодона для применения в педиатрии и способ лечения ими
Weisler et al. Fed and Fasted Administration of a Novel Extended‐Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD
JP2009149545A (ja) 内服液剤
CN115645357A (zh) 一种拉考沙胺口服溶液处方及其制备工艺
Sawant et al. A randomized pilot study to evaluate the stability, taste, and palatability of a novel liquid formulation of tenapanor
JP7627353B2 (ja) チザニジン液体製剤及びその用途
EP3755373A1 (en) Oral solutions comprising tramadol
US20250288560A1 (en) Tizanidine liquid preparation and use thereof
Tablets DESLORATADINE ALLERGY CONTROL

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250131

R150 Certificate of patent or registration of utility model

Ref document number: 7629453

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150